Patient immunologic phenotype
| . | Patient . | Controls . |
|---|---|---|
| Lymphocyte subpopulation* | ||
| CD3εhigh | 17 (0.4) | 1111-5183 |
| CD3εlow | 2688 (63.7) | NA |
| CD20+ | 1401 (33.2) | 144-671 |
| CD16+ | 174 (4.1) | 152-709 |
| CD56+ | 0 | 223-1040 |
| Serum Ig level† | ||
| IgG‡ | 2310 | 192-515 |
| IgA | 213 | 12-31 |
| IgM | 248 | 39-92 |
| IgE | 27 | 0-150 |
| Proliferative stimulus§ | ||
| Medium | 1254 | 693 ± 825 |
| PHA | 1989 | 222 330 ± 50 643 |
| Con A | 3695 | 208 534 ± 52 592 |
| PWM | 7224 | 135 520 ± 35 077 |
| Candida | 1000 | 45 431 ± 30 989 |
| Anti-CD3ε | 131 | 122 953 ± 44 094 |
| Autologous cells | 745 | 3163 ± 2874 |
| Allogeneic cells | 5520 | 59 818 ± 38 445 |
| . | Patient . | Controls . |
|---|---|---|
| Lymphocyte subpopulation* | ||
| CD3εhigh | 17 (0.4) | 1111-5183 |
| CD3εlow | 2688 (63.7) | NA |
| CD20+ | 1401 (33.2) | 144-671 |
| CD16+ | 174 (4.1) | 152-709 |
| CD56+ | 0 | 223-1040 |
| Serum Ig level† | ||
| IgG‡ | 2310 | 192-515 |
| IgA | 213 | 12-31 |
| IgM | 248 | 39-92 |
| IgE | 27 | 0-150 |
| Proliferative stimulus§ | ||
| Medium | 1254 | 693 ± 825 |
| PHA | 1989 | 222 330 ± 50 643 |
| Con A | 3695 | 208 534 ± 52 592 |
| PWM | 7224 | 135 520 ± 35 077 |
| Candida | 1000 | 45 431 ± 30 989 |
| Anti-CD3ε | 131 | 122 953 ± 44 094 |
| Autologous cells | 745 | 3163 ± 2874 |
| Allogeneic cells | 5520 | 59 818 ± 38 445 |
NA indicates not applicable; PHA, phytohemagglutinin; Con A, concanavalin A; PWM, pokeweed mitogen.
Values are expressed as cells/mm3 or (percentage of lymphocytes). Control values are the 95% confidence intervals for 1550 healthy controls.
Values are expressed as mg/dL (IgG, IgA, IgM) or U/mL (IgE). Normal values are the 95% confidence intervals for 12 6-month-old control subjects.
The patient was receiving IVIG when the IgG level was measured.
Values are cpm [3H]thymidine incorporation. Controls values are the mean ± SD of responses in 167 healthy controls.